Imatinib impurity F:Exports & Compliance White Paper 2026

I. Executive Summary

Imatinib impurity F, chemically 4-methyl-N3-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine and listed under CAS 152460-10-1, occupies a dual role in the oncology supply chain. It is the penultimate aromatic amine intermediate in most industrial imatinib routes, and it is simultaneously a specified related substance in the finished active substance, because unreacted amine can survive the final amide-forming step and be carried into the drug substance. This white paper treats the compound accordingly: as an analytical reference standard, a genotoxic-impurity control subject and a documentation deliverable for pharmaceutical customers, not as a bulk commodity to be traded in volume. It makes no therapeutic claim and gives no dosing or use instruction of any kind.

The commercially decisive fact about this molecule is that it is an aniline-type aromatic amine. Aromatic amines are handled under ICH M7 as a cohort-of-concern class of high-potency mutagenic carcinogens, which means the acceptable intake cannot be read off a default specification but must be established either from compound-specific carcinogenicity and mutagenicity data or from a threshold-of-toxicological-concern calculation, then defended with purge-factor reasoning and a validated trace-level analytical method. Suppliers who cannot speak to acceptable intake, limit derivation and limit of quantitation are not selling a compliant impurity standard; they are selling an uncharacterised powder.

The sections below cover the physicochemical and structural basis for that classification, the route-class chemistry and purge strategy used to make and to eliminate the compound, the reference-standard manufacture and certification model built on ISO 17034 and ISO/IEC 17025, the analytical and quality-system framework of ICH Q3D, Q2(R1) and Q14, and the containment, packaging and logistics practices appropriate to a potent aromatic amine. Regional coverage addresses the Chinese, Indian and European ecosystems.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Structurally the molecule presents a pyridin-3-yl group attached to a pyrimidine ring, with the pyrimidine C2 position bearing an anilino nitrogen that links to a 4-methyl-substituted phenylene diamine. It is the same heteroaromatic core found in imatinib itself, minus the 4-(methylpiperazinylmethyl)benzoyl amide side chain. Because the compound is a process intermediate and a related substance rather than an active pharmaceutical ingredient, there is no pharmacological or clinical narrative to discuss. The properties that matter to buyers are structural alerts, ionisation behaviour, chromatographic response and solid-state stability, all of which drive how the material must be specified, handled and analysed.

• Identity, Formula and Physicochemical Profile: The molecular formula C16H15N5 gives a relative molecular mass of approximately 277.3, with a planar three-ring heteroaromatic system, a primary aromatic amine and a secondary anilino nitrogen, and a pyridine nitrogen as the principal basic centre with a conjugate-acid pKa in the weakly acidic region, so retention and extraction behaviour are strongly pH dependent.
• The Genotoxic Alert That Defines the Specification: The free aniline function is the structural alert that places the compound in ICH M7 cohort-of-concern territory, alongside aflatoxin-like, N-nitroso and alkyl-aziridine structures; it therefore requires either compound-specific mutagenicity data or a threshold-of-toxicological-concern derived acceptable intake rather than an ordinary ICH Q3A reporting threshold.

2.2 Synthesis and Manufacturing Technologies

Industrial manufacture of the compound follows the same route class as imatinib itself, stopped one step earlier. A pyridin-3-yl enaminone is condensed with an appropriately substituted aryl guanidine to build the 2-aminopyrimidine ring system, and the nitro group of the aryl partner is then reduced to liberate the free aromatic amine. Two process decisions dominate quality: how completely the nitro precursor is reduced, and how much residual amine is carried forward if the material is used as an intermediate rather than isolated as a standard. Both are controlled by in-process testing rather than by end-product testing alone.

• Cyclocondensation and Catalytic Reduction: Ring construction by guanidine and enaminone cyclocondensation followed by catalytic hydrogenation or transfer hydrogenation of the nitro group are the established route classes; the reduction step is the one that generates the aromatic amine alert and is therefore the critical process parameter for impurity-control purposes.
• Purge-Factor Reasoning and Downstream Removal: Where the amine is generated as an intermediate, its removal is demonstrated by purge-factor arguments built on reactivity, solubility, crystallisation and washing behaviour across the subsequent amide-coupling and isolation steps, supported by spiking and fate studies rather than by assumption.

2.3 Core Application Matrix

• Analytical Reference Standard: Certified material used for peak identification, system suitability, calibration and quantitation in HPLC and LC-MS or GC-MS related-substance methods for imatinib drug substance and drug product, supplied in accurately weighed ampoules.
• Genotoxic-Impurity Risk Assessment Support: Material for bacterial reverse mutation testing, in silico and expert review, purge-factor spike studies and acceptable-intake justification within an ICH M7 control strategy submitted to regulators.
• Generic API Development and Dossier Support: Supply to licensed API manufacturers assembling impurity profiles for DMF, ASMF, CEP and ANDA submissions, including batch records, analytical methods and impurity- fate documentation.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand is derived entirely from the generic and originator imatinib industry and from the regulatory remediation programmes that surround it. Three drivers dominate: continuation and renewal of abbreviated and marketing-authorisation filings for imatinib, intensifying scrutiny of mutagenic impurities following the nitrosamine episode, and the growth of outsourced analytical testing in which contract laboratories must hold certified impurity standards on the shelf. Volumes are small. A single campaign may produce a few grams of standard that supply hundreds of customers over several years, which is why catalogues, certification and document control matter more to economics than synthesis throughput.

3.2 Capacity Distribution and Export Flows

Synthesis capacity resides overwhelmingly in China and India, where imatinib API and its intermediates are produced at scale and where impurity synthesis is a natural by-product of route development capability. Certification capacity is more evenly distributed, with accredited reference-material producers in Europe and North America performing quantitative NMR, mass-balance purity assignment and uncertainty budgeting. Export flows therefore move from Asian synthesis sites to Western certification and distribution hubs, and then onward to pharmaceutical quality-control laboratories worldwide.

3.3 Market Bifurcation and Pricing Dynamics

The market splits sharply between analytical-grade material accompanied by a routine certificate of analysis and certified reference material produced under ISO 17034 with an ISO/IEC 17025 calibration or testing scope, a stated uncertainty budget and a defined retest date. The price differential between the two is large, and it reflects certification labour and metrology rather than chemical value. A third tier, GMP-grade campaign material made for use in a specific filing, carries documentation costs that exceed the cost of the molecule. Buyers should note that the dominant cost driver in any quotation is documentation depth, and should specify the intended regulatory use at enquiry stage.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Compliance obligations attach to both the substance and the transaction. The substance must be correctly classified, registered and documented in each jurisdiction in which it is placed on the market, and the transaction must be qualified, because a potent aromatic amine supplied without end-use visibility is a regulatory and reputational liability for everyone in the chain. The instruments below are those a competent supplier should be able to evidence without preparation.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH Status, CLP Classification and SVHC Screening: The substance must have a defensible REACH position, whether as a registered substance, a registered intermediate under strictly controlled conditions or a valid exemption, together with a harmonised or self-classified CLP entry, a compliant safety data sheet and documented screening against the candidate list and the Annex XVII aromatic amine provisions.
• EU GMP, ICH M7 and EDQM Reference Standards: Marketing authorisation holders must demonstrate mutagenic-impurity control in accordance with ICH M7 as applied in the EU, and many quality-control laboratories align their specification and method to the pharmacopoeial and EDQM reference-standard framework, so an EU-facing supplier should expect questions on both fronts.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Inventory and FDA Impurity Expectations: Commercial import into the United States requires a confirmed TSCA inventory or exemption position, correct certification at entry and appropriate labelling, while FDA review of abbreviated applications applies ICH Q3A and Q3B with ICH M7 overlay for the aromatic amine alert.
• Nitrosamine-Adjacent Screening and Genotoxic Guidance: Aromatic amines are recognised nitrosamine precursors and are routinely included in nitrosamine risk assessments and FDA and EMA guidance on mutagenic impurities, so suppliers should expect requests for nitrosamine and nitrosatable-amine screening data alongside the standard impurity package.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Although campaigns for this compound are small, they sit inside larger imatinib intermediate operations whose environmental profile is scrutinised in supplier audits. Solvent load from condensation and reduction steps, metal residues from catalytic hydrogenation and the treatment of aromatic amine bearing effluent are the three issues that consistently attract attention in supplier audits.

5.1 Carbon Footprint and Circular Economy

Energy and solvent intensity are dominated by the reduction and isolation steps and by the multiple crystallisations needed to reach reference-standard purity. Practical measures include solvent recovery and reuse, catalyst recovery and recycling of precious metal, and process mass-intensity reporting per kilogram of isolated standard. Suppliers able to present a Scope 1 and Scope 2 inventory, solvent-recovery rates under an ISO 14001 certified environmental management system increasingly win preferred status in customer audits.

5.2 Sustainable Sourcing and Traceability

Traceability expectations extend from starting material origin through catalyst provenance to elemental impurity control under ICH Q3D. Customers should require documented origin of the nitroaniline and guanidine precursors, a statement on residual metal catalysts, an ICH Q3D risk assessment covering Class 1 and Class 2A and 2B elements, and a change-control undertaking that any route, solvent or catalyst change triggers advance notification and re-assessment of the impurity and elemental profile.

VI. Supply Chain Resilience and Export Logistics

Reference-standard consignments are small, fragile in value terms and time-critical to laboratory schedules. The physical risks are moisture uptake, light-induced discoloration of the aromatic amine and loss of certified mass through poor closure; the commercial risks are a broken storage record and documentation that does not match the vial. Logistics planning should treat the certificate, the storage statement and the packaging as one deliverable rather than three.

6.1 Packaging Standards and Moisture/Contamination Control

• Light-Protected, Sealed Primary Packaging: Amber glass ampoules or vials with polytetrafluoroethylene-lined closures, sealed under inert gas where the stability data support it, with desiccant and light-blocking secondary packaging and a documented water content and residual-solvent statement on the certificate.
• Documentation Set and Chain of Custody: Certificate of analysis stating identity, purity-assignment method, uncertainty, retest date and storage condition, plus safety data sheet, end-use declaration reference, tamper-evident sealing and batch traceability back to the synthesis campaign.

6.2 Dangerous Goods Identification and Transit Protocols

Most shipments of this compound are small enough to move as non-dangerous or minimally regulated goods, but that conclusion must follow from classification data rather than be assumed, because aromatic amines frequently attract acute toxicity and environmental hazard classifications under CLP and GHS. Where a classification applies, UN-specification packaging, correct hazard labelling and a dangerous-goods declaration under IMDG, ADR or IATA rules are mandatory, and a trained shipper must handle the consignment. Temperature-controlled or refrigerated transit is used where stability data require it, with continuous logging and defined excursion thresholds, and air freight is generally preferred because short transit protects the certified storage record.

VII. Enterprise Global Expansion Strategy Guide

For CDMOs and exporters building a position in impurity reference standards, credibility is the product. Three priorities follow from that: metrological competence, regulatory documentation capability and disciplined customer qualification.

1. Build Metrological Credibility: Invest in ISO 17034 reference-material producer accreditation and an ISO/IEC 17025 testing scope, assign purity by quantitative NMR supported by mass balance, HPLC, water, residual solvent and elemental data, and publish a defensible uncertainty budget rather than a single purity figure.
2. Sell Documentation, Not Powder: Package the standard with method-validation data under ICH Q2(R1) and Q14, stability and retest evidence, ICH M7 acceptable-intake reasoning and DMF or ASMF support material, so the customer's dossier work is reduced rather than merely supplied with a vial.
3. Qualify Every Customer and Contain Every Gram: Restrict supply to licensed pharmaceutical, analytical and research organisations, apply Know-Your-Customer screening and end-use declarations, and operate to an occupational exposure band derived from a health-based exposure limit, with isolator or glovebox handling, dedicated equipment and documented cleaning verification.

VIII. Conclusion

Imatinib impurity F is best understood as a control artefact of the imatinib industry rather than a product in its own right. Its commercial value lies in what it allows a quality-control laboratory and a regulator to conclude: that a mutagenic aromatic amine is identified, quantified, purged and documented to an acceptable intake derived under ICH M7. That value is created by metrology, by method validation and by documentation, and it is destroyed by any supplier that treats the compound as a commodity powder.

The compliance perimeter is equally clear. No therapeutic claim is made for this material, no dosing or administration guidance is provided, and supply is restricted to licensed pharmaceutical and analytical customers under Know-Your-Customer screening and end-use declaration. Organisations that combine ISO 17034 accredited certification with ICH M7 reasoning, health-based-exposure-limit containment and rigorous change control will remain the preferred partners as mutagenic-impurity and nitrosamine-adjacent scrutiny continues to tighten.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Imatinib impurity F (4-methyl-N3-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine) Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Imatinib impurity F (4-methyl-N3-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine) supply chain:

• China Imatinib Intermediate and Impurity Synthesis Base: Chinese producers combine deep imatinib route experience with rapid custom impurity synthesis, offering milligram to gram quantities at short lead times; buyers should test whether the quoted material carries a genuine purity-assignment basis and an uncertainty statement rather than a chromatographic area percentage.
• India Generic API and Dossier-Linked Impurity Capability: Indian suppliers integrate impurity synthesis with DMF, ASMF and ANDA documentation experience, making them strong partners where the standard must be delivered with method validation, purge-factor data and filing-ready impurity justification.
• European Union Accredited Reference-Standard Ecosystem: EU producers and official medicines control laboratories supply ISO 17034 accredited certified reference material with quantitative NMR assignment, uncertainty budgets, retest dates and pharmacopoeial alignment, serving customers whose quality systems demand the highest metrological assurance.